Tetrandrine sensitizes nasopharyngeal carcinoma cells to irradiation by inducing autophagy and inhibiting MEK/ERK pathway
Open Access
- 11 August 2020
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 9 (19) , 7268-7278
Abstract
Radioresistance was the main reason for local recurrence and metastasis of nasopharyngeal carcinoma. Tetrandrine is reported as an antitumor drug via inducing cell cycle arrest and apoptosis. In this study, the radiosensitization effects of maximum noncytotoxic doses of tetrandrine in nasopharyngeal carcinoma were analyzed both in vitro and in vivo, using MTT assay, western blot, TUNEL, and HE staining. It was found that the maximum dose of tetrandrine inhibited the phosphorylation of ERK and MEK induced by irradiation, and significantly enhanced irradiation‐induced cell growth inhibition in nasopharyngeal carcinoma cells CNE1, CNE2, and C666‐1. The ERK activator and overexpression of ERK reversed the radiosensitization effect of tetrandrine. About 50 mg/kg of tetrandrine which was used as the maximum noncytotoxic dose of tetrandrine in vivo, enhanced the radiosensitivity of the xenograft tumor and increased the apoptosis rate of the xenograft tumor cells caused by irradiation, while did not raise the side effect of the treatment. Moreover, tetrandrine increased autophagy in nasopharyngeal carcinoma cells. These results suggested that the maximum noncytotoxic dose of tetrandrine sensitized nasopharyngeal carcinoma to irradiation by inhibiting MEK/ERK pathway and inducing autophagy.Keywords
Funding Information
- National Natural Science Foundation of China (81970859)
This publication has 34 references indexed in Scilit:
- Abrogation of the p38 MAPK α signaling pathway does not promote radioresistance but its activity is required for 5-Fluorouracil-associated radiosensitivityCancer Letters, 2013
- COX-2 promotes breast cancer cell radioresistance via p38/MAPK-mediated cellular anti-apoptosis and invasivenessTumor Biology, 2013
- Modulation of Sensitivity to Antitumor Agents by Targeting the MAPK Survival PathwayCurrent Pharmaceutical Design, 2013
- The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approachesExpert Opinion on Therapeutic Targets, 2012
- Enhancement of Radiosensitivity and the Potential Mechanism on Human Esophageal Carcinoma Cells by TetrandrineCancer Biotherapy and Radiopharmaceuticals, 2011
- Combination of Tetrandrine with cisplatin enhances cytotoxicity through growth suppression and apoptosis in ovarian cancer in vitro and in vivoCancer Letters, 2011
- Treatment Outcomes After Radiotherapy Alone for Patients With Early-Stage Nasopharyngeal CarcinomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009
- Tetrandrine suppresses tumor growth and angiogenesis of gliomas in ratsInternational Journal of Cancer, 2009
- Induction of G2/M arrest, endoreduplication, and apoptosis by actin depolymerization agent pextenotoxin-2 in human leukemia cells, involving activation of ERK and JNKBiochemical Pharmacology, 2008
- Inhibitory Effect of Tetrandrine on Pulmonary Metastases in CT26 Colorectal Adenocarcinoma–Bearing BALB/c MiceThe American Journal of Chinese Medicine, 2004